Course of a HBsAg positive liver transplantation in a hepatitis B and D virus coinfected recipient

Annals of Hepatology

Volumn 10, Issue 3, 2011, Pages 355-360

  Bahde, Ralf ^a   Hölzen, Jens P ^a   Wolters, Heiner H ^a   Schmidt, Hartmut H J ^a   Thomas Bock, C ^b   Lügering, Andreas ^a   Spieker, Tilmann ^c   Senninger, Norbert ^a   Brockmann, Jens G ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Hepatitis B; Hepatitis D; Liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; ALKALINE PHOSPHATASE; ANTIDIURETIC AGENT; ASPARTATE AMINOTRANSFERASE; GANCICLOVIR; HEPATITIS ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; LAMIVUDINE; PEGINTERFERON ALPHA2B; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CADAVER DONOR; CASE REPORT; CHRONIC HEPATITIS; CYTOMEGALOVIRUS INFECTION; DECOMPENSATED LIVER CIRRHOSIS; DELTA AGENT HEPATITIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGUS VARICES; GRAFT RECIPIENT; HEPATITIS B; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFORMED CONSENT; LEUKOPENIA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER TRANSPLANTATION; MALE; MEDICAL HISTORY; MIXED INFECTION; PATIENT COMPLIANCE; PORTAL HYPERTENSION; POSTOPERATIVE PERIOD; PROPHYLAXIS; PROTHROMBIN TIME; REINFECTION; RETRANSPLANTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA; VIRUS REPLICATION;

EID: 79959421560     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31550-9     Document Type: Article

References (25)

1. Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: A survery of North American, European, and Asian-Pacific transplant programs. Liver Transpl 2009; 15: 223-32.
2. Gonzalez-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, Lau JY. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus- negative recipient. Transplantation 1994; 58: 114-16.
3. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-8.
4. Hwang SH, Lee SG, Park KM, Kim KH, Ahn CS, Oh HB, Moon DB, et al. Five-year follow-up of a hepatitis B virus-positive recipient of a hepatitis B surface antigen-positive living donor liver graft. Liver Transpl 2006; 12: 993-7.
5. Soejima Y, Shimada M, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, Nakamuta M, et al. Successful living donor liver transplantation using a graft from a hepatitis B surface antigen-positive donor. Liver Int 2007; 27: 1282-6.
6. Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40.
7. Rizetto M. Hepatitis D: Clinical features and therapy. Dig Dis 2010; 28: 139-43.
8. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39: S212-S19.
9. Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Aricò S, Calzia R, et al. Chronic hepatitis in carriers of hepatitis B surface antigen, with intrahepatic expression of the delta antigen. An active and progressive disease unresponsive to immunosuppressive treatment. Ann Intern Med 1983; 98: 437-41.
10. Rifai K, Wedemeyer H, Rosenau J, Klempnauer J, Strassburg CP, Manns MP, Tillmann HL. Longer survival of liver transplant recipients with hepatits virus coinfections. Clin Transplant 2007; 21: 258-64.
11. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Eng J Med 1993; 329: 1842-7.
12. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, Alessandria C, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transplant 2005; 11: 402-9.
13. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-S85.
14. Samuel D, Zignego AL, Reynes M, Feray C, Arulnaden JL, David MF, Gigou M, et al. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333-9.
15. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-6.
16. Smedile A, Casey JL, Cote PJ, Durazzo M, Lavezzo B, Purcell RH, Rizzetto M, et al. Hepatitis D viremia following or thotopic liver transplantation involves a typical HDV virion with a hepatitis B surface antigen envelope. Hepatology 1998; 27: 1723-9.
17. McCaughan GW, Spencer J, Koorey D, Bowden S, Bartholomeusz A, Littlejohn M, Verran D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globuline. Liver Transpl Surg 1999; 5: 512-19.
18. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-33.
19. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. J Viral Hepat 2005; 12: 2-9.
20. Castelnau C, Le Gal F, Ripault MP, Gordien E, Martinot-Peignoux M, Boyer N, Pham BN, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006; 44: 728-35.
21. Erhardt A, Gerlich W, Starke C Wend U, Donner A, Sagir A, Heintges T, et al. Treatment of chronic hepatitis delta with pegylated interferon-alpha2b. Liver Int 2006; 26: 805-10.
22. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt A, et al. Long-term efficacy of tenofovir monotherapy for hepatits B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
23. Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B. Value Health 2010 Sep 3 (Epub ahead of print).
24. Mansour W, Ducancelle A, Le Gal F, Le Guillou-Guillemette H, Abgueguen P, Pivert A, Calès P, et al. Resolution of chronic hepatitis delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol 2010; 47: 97-9.
25. Bordier BB, Ohkanda J, Liu P, Lee SY, Salazar FH, Marion PL, Ohashi K, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus (HDV). J Clin Invest 2003; 112: 407-14.